The guidelines define the goal of treatment for most patients as maximizing survival and achieving prompt and complete (or near-complete) elimination of angina with a return to normal activities . Traditional therapies for chronic stable angina include β-blockers, calcium channel blockers, and long-acting nitrates . For some patients, use of these agents may be limited by key adverse effects of β-blockers (bradycardia, heart block,
hypotension, bronchospasm) and calcium channel blockers (ankle edema, headache, flushing, hypotension), as well as tolerance associated with long-term use of nitrates . The sodium channel inhibitor ranolazine is indicated to treat chronic stable angina and may be used with β-blockers, calcium channel blockers, and nitrates . When learn more taken in combination with standard doses of β-blockers or calcium channel blockers, ranolazine improved exercise duration and time to ischemia, and reduced the frequency of angina attacks and nitroglycerin use in patients with severe chronic angina . In a pilot study comparing ranolazine and placebo for 4 weeks each in a
crossover fashion in 20 women with angina and evidence of myocardial ischemia but no obstructive coronary artery disease, RG-7388 datasheet scores were significantly better for ranolazine on the Seattle Angina Questionnaire (SAQ) subscales assessing physical functioning (91.7 vs. 83.3; p = 0.046), angina stability (75.0 vs. 50.0; www.selleckchem.com/products/poziotinib-hm781-36b.html p = 0.008), and QoL (75.0 vs. 66.7; p = 0.021) . A prospective QoL assessment performed alongside the MERLIN (Metabolic Efficiency with Ranolazine for Less Ischemia in Non–ST-elevation acute coronary syndromes)-TIMI
36 trial showed small but statistically significant effects of ranolazine on disease-specific health status and QoL over 12 months’ follow-up . Little is known regarding the impact of ranolazine on QoL over longer treatment durations. The present patient survey was designed to evaluate the effect of long-term (up to >4 years) ranolazine treatment on self-reported angina severity, frequency, and QoL in patients with chronic angina. 2 Methods A 40-question survey was distributed from 6 17-DMAG (Alvespimycin) HCl April to 10 May 2011, via email and telephone, to a panel of patients currently receiving ranolazine treatment. Patients were invited to participate in the panel through website registration (Ranexa.com and SpeakFromTheHeart.com), by opting-in for research, or via savings program participation. Patients answered screening questions (for which they received honoraria) in order to join the panel; the screening criteria included age ≥18 years; being on ranolazine treatment prescribed by a healthcare professional (not including use of only a sample); and no employment of themselves or any immediate family member by a pharmaceutical manufacturer, medical equipment manufacturer, market research or advertising firm, medical office, clinic, or hospital. Panel members were subsequently invited and opted to participate in the survey.